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Abstract Noroviruses (NoVs) are one of the leading
causes of acute gastroenteritis worldwide. NoV GII-4 VP1
protein was expressed in a recombinant baculovirus system
using Sf9 insect cells. Several methods for puriﬁcation and
concentration of virus-like particles (VLPs) were evalu-
ated. Electron microscopy (EM) and histo-blood group
antigen (HBGA) binding assays showed that repeated
sucrose gradient puriﬁcation followed by ultraﬁltration
resulted in intact VLPs with excellent binding to H type 3
antigens. VLPs were stable for at least 12 months at 4C,
and up to 7 days at ambient temperature. These ﬁndings
indicate that this method yielded stable and high-quality
VLPs.
Noroviruses (NoVs) cause sporadic acute nonbacterial
gastroenteritis in all age groups [12, 13]. NoVs are divided
into ﬁve genogroups, GI to GV, of which GI and GII strains
mostly affect humans [21]. Recently, NoV genotype GII-4
has been responsible for the majority of sporadic gastro-
enteritis cases and outbreaks [13]. The NoV genome con-
sists of a single-stranded RNA of about 7.6 kb, organized
into open reading frames (ORF 1–3). ORF-1 codes for the
RNA-dependent RNA polymerase, and ORF-2 and -3
encode the two structural proteins VP1 and VP2 [10].
Expression of the capsid VP1 gene by recombinant
baculoviruses leads to self-assembly into empty virus-like
particles (VLPs) that are morphologically and antigenically
similar to native NoV [9]. NoV VLPs are widely used as
antigens in diagnostic serological assays and as candidate
vaccines against NoVs [2, 7]. NoV VLPs are highly stable
and resistant to variable conditions, particularly to low pH
[1, 9].
There are limitations in NoV VLP production in terms
of inadequate yield and quality of the VLPs [1, 3, 9, 20].
Both sucrose and CsCl gradients ultracentrifugation have
been used for puriﬁcation of NoV VLPs [1, 7, 9, 17], even
though studies on rotavirus-like particles demonstrated a
low yield and impurities resulting from CsCl gradient
puriﬁcation [16].
In the present study, we compared commonly used
methods for NoV GII-4 VLP puriﬁcation [1, 14, 17] and
concentration [6, 19], considering the purity, yield, mor-
phological integrity, antigenicity and functionality of the
puriﬁed VLPs.
The steps for cloning the NoV GII-4 (GenBank sequence
database accession number AF080551) full-length capsid
gene are described elsewhere [11].
VLPs were produced in Sf9 insect cells infected with the
recombinant baculovirus according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Baculovirus titers
expressed as the multiplicity of infection (MOI) of the P2
stocks were determined using a BacPak Rapid Titer Kit
(Clontech Laboratories, Mountain View, CA).
At day 6, infected cell culture (200 ml) was clariﬁed
by centrifugation at 30009g for 30 min at 4C. VLPs in
the supernatant were concentrated by ultracentrifugation
(L8-60M ultracentrifuge, Beckman SW-32.1 Ti rotor) at
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0.2 M Tris–HCl, pH 7.3. VLPs were loaded onto a 10–60%
discontinuous sucrose gradient and ultracentrifugated at
100,0009g for 1 h at 4C as described before [17]. Frac-
tions were collected by bottom puncture. The fractions
containing VLPs were pooled. An additional discontinuous
sucrose gradient (35–60%) ultracentrifugation was per-
formed. Sucrose was removed by overnight dialysis against
1 liter of PBS. VLPs were concentrated by dialysis against
polyethylene glycol (PEG; 50%) [6] or by ultraﬁltration
[19]. VLPs were concentrated using an Amicon Ultra
30 kDa centrifuge ﬁlter device (Millipore Corporation,
Billerica, Germany). VLPs were stored at 4C in PBS.
Alternatively, a less time-consuming sucrose density
gradient puriﬁcation method was employed [14]. Clariﬁed
supernatants were pelleted twice by ultracentrifugation.
Pellets were resuspended in 0.2 M Tris–HCl, pH 7.3, and
placed on a discontinuous sucrose density gradient
(10–60%) for ultracentrifugation at 100,0009g for 16 h at
4C. The VLP band, which was visible at the 35% sucrose
layer, was collected. Sucrose was removed by dialysis
against 1 liter of PBS, and VLPs were concentrated by
ultracentrifugation at 100,0009g for 2 h at 4C.
In addition, clariﬁed supernatants were concentrated, and
the pellets were resuspended in sterile water. VLPs were
sedimented by ultracentrifugation through cesium chloride
(CsCl) (0.4 g/ml) at 116,0009g for 18 h at 4C as described
earlier by others [1]. CsCl was removed by dialysis against
PBS, and VLPs were concentrated using an Amicon
Ultraﬁlter.
The total protein content of the puriﬁed VLP preparation
was determined using the Pierce BCA Protein Assay
(Thermo Science, Rockford, USA). Endotoxin levels in the
VLP preparations were quantiﬁed using the Limulus ame-
bocytelysate(LAL)assay(Lonza,Walkersville,MD,USA).
Thelevelofendotoxinwas\0.1 EU/10 lgofprotein,which
is below the international standard of B30 EU/20 lgo f
protein [15]. All samples were analyzed for protein expres-
sion by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and western blot. The presence of
NoV VLPs was veriﬁed by electron microscopy (EM). VLP
preparations were negatively stained with 3% uranyl acetate
(UA),pH4.6.TheVLPswereexaminedusinganFEITecnai
F12 electron microscope operating at 120 kV.
Binding of GII-4 VLPs to carbohydrate receptors was
examinedbythehisto-bloodgroupantigen(HBGA)binding
assay as described by others [18], with slight modiﬁcations.
Brieﬂy, VLPs were coated at 50 ng/well, and synthetic
biotinylated H type 3 and Lewis
b histo-blood group carbo-
hydrates (Lectinity Holdings Inc. Moscow, Russia) were
used in serial threefold dilutions, starting from 6 lg/ml.
Wells lacking the synthetic carbohydrates were used as a
negative control.
The conditions for Sf9 cell infections were optimized in
order to obtain a high yield of the VLPs. For recombinant
baculovirus P2 stock, an MOI of 1 was found to be optimal,
and VLPs were harvested from the supernatant after 6 days
of infection. VLPs were further puriﬁed by several differ-
ent procedures, as described in Fig. 1a.
The best yield (2–3 mg/200 ml) was obtained after the
puriﬁcation procedure described in Fig. 1a, panel B. In
comparison, the method described in Fig. 1a, panel C, yiel-
ded a ten times lower amount of NoV capsid VLPs. The
purityoftheVLPs obtainedbyeach method wasdetermined
by 12% SDS-PAGE and staining of the proteins with Page-
Blue (Fig. 1b). 1 lg of the total protein was loaded into each
lane. Each method resulted in equally pure protein bands
corresponding to the size of the NoV capsid. Residual PEG
presentintheVLPs,concentratedbyPEGdialysis,mayhave
interfered with the protein concentration determination, and
Fig. 1 Puriﬁcation, concentration and characterization of NoV VLPs.
a Several puriﬁcation procedures (A–D) were used, and the purity,
morphology, antigenicity and yield of the VLPs were compared.
b NoV capsid protein analysis by 12% SDS-PAGE. c Western blot
analysis using a human convalescent serum against norovirus GII-4.
d EM of puriﬁed NoV VLPs observed at a magniﬁcation of 930,000.
Bar 100 nm. Samples from puriﬁcation procedures A, B, C, and
D correspond to lanes and panels A, B, C, and D, respectively.
M protein weight marker
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observed (Fig. 1b, lane A). NoV capsid identity and anti-
genicity of the VLPs were assayed by western blot using
humanNoV-speciﬁcconvalescentsera(Fig. 1c).Theresults
showpureNoVcapsidproteinswithoutdegradationandwith
similar antigenicity for each of the puriﬁcation methods.
Next, we determined the morphological integrity and
homogeneity of the VLPs by EM (Fig. 1d). The VLPs
obtained by puriﬁcation with sucrose density gradients fol-
lowed by dialysis and either ultraﬁltration (Fig. 1d, panel B)
orultracentrifugation(Fig. 1d,panelC)wereapproximately
38 nm in size, with the classical appearance of NoV capsid
VLPs. By contrast, CsCl puriﬁcation (Fig. 1d, panel D) and
concentration of the VLPs by dialysis against PEG (Fig. 1d,
panel A) resulted in VLPs of heterogeneous size, which
appeared broken and aggregated. The VLPs puriﬁed and
concentrated by the method schematically presented in
Fig. 1a, panel B, were of the best quality and were subjected
to further analysis.
To determine the optimal storage conditions and stability
of the NoV capsid VLPs, VLPs were treated under different
conditions,andthesampleswereanalyzedbySDS-PAGEto
test their protein integrity (Fig. 2a) and by EM to examine
their morphology (Fig. 2b). VLPs were stable for at least 12
months at 4C in PBS, pH 7.4 (Fig. 2a and b, panel 1), and
at room temperature (23C) up to 7 days (Fig. 2a and b,
panel3).TheVLPswithstoodthesterileﬁltrationconditions
when 0.22-lm ﬁlters (Durapore, Millipore, Ireland) were
used. Next, we intentionally disrupted the VLP morphology
by heat treatment at 60C for 1 h (Fig. 2b, panel 4) [1]
without degrading the capsid protein (Fig. 2a, lane 4).
An HBGA binding assay [8, 18] was used to test the
functionality of the puriﬁed VLPs as well as to determine
the signiﬁcance of the conformational binding sites on the
VLP, which would presumable require intact VLPs. A
comparison of the binding of VLPs puriﬁed by sucrose
gradientcentrifugationandbyCsClsedimentation,aswellas
heat-treated VLPs (60C, 1 h), to synthetic biotinylated H
type 3 carbohydrate is shown in Fig. 3. The binding was
clearly dependent on the morphology and preserved struc-
ture of the VLPs, with the lowest level of binding observed
with the heat-treated VLPs with disrupted conformational
binding sites. Lewis
b antigen was used as a control in the
assay, and this did not bind to any of the VLPs (Fig. 3).
NoV VLPs have been used extensively to study protein
interactions [8], and virus assembly [17], and have been
used as a tool in diagnostic serological assays [7]. Clinical
trials have been performed with the NoV VLPs used as a
vaccine [2]. For all these applications, high-quality VLPs
would be preferable. In this study, different methods of
VLP puriﬁcation and concentration were used, and the
purity, integrity, morphology, antigenicity and functional-
ity of the GII-4 NoV VLP preparations were examined.
VLPs puriﬁed by each method (Fig. 1a, methods A–D)
had a similar appearance and migration pattern on the SDS-
PAGE gel. A western blot with a human convalescent
serum from an individual infected with GII-4 conﬁrmed the
identity of the capsids and the lack of degradation products.
The reason for the lower protein yield after puriﬁcation
procedure C might have been that a narrow visible band of
VLPs was collected from 35% sucrose, causing some of the
protein to be omitted, thus affecting the yield. However, a
yield of up to 2–3 mg of VLPs, which was obtained by the
best puriﬁcation method described in the present study, is
remarkably high when compared to other reports [3, 4].
EM analysis of the morphological integrity and homo-
geneity of the VLPs showed that VLPs obtained by puri-
ﬁcation with sucrose density gradients followed by
ultraﬁltration or ultracentrifugation (procedures B and C,
Fig. 2 Stability of NoV VLPs. The stability was analyzed by SDS-
PAGE (a) and EM (b) at a magniﬁcation of 930,000. Bar 100 nm.
NoV capsid VLPs after 8 months at 4C( lane 1 and panel 1), sterile
ﬁltration (lane 2 and panel 2), 7 days at room temperature (lane 3 and
panel 3) and heat treatment (60C, 1 h) (lane 4 and panel 4)
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Fig. 3 Binding of NoV VLPs to synthetic ABH histo-blood group
antigens. Sucrose-puriﬁed VLPs (Sucrose VLPs, puriﬁed according to
procedure B in Fig. 1a), heat-denatured NoV VLPs (60C, 1 h) (Heat-
treated VLPs) and CsCl-puriﬁed VLPs (CsCl VLPs) were tested for
binding to H type 3 and Lewis
b carbohydrates at the indicated
concentrations. The pH value in the binding assay was 7.4
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123respectively) were homogenous and intact, and approxi-
mately 38 nm in size. However, CsCl-puriﬁed VLPs
appeared heterogeneous in size, with a few broken parti-
cles, although comparable to the morphology seen by
others [7]. CsCl puriﬁcation is known to introduce several
impurities at the end of the process and cause aggregation
of the VLPs during storage [5]. The poorest morphology
was seen after concentration of the VLPs by dialysis
against PEG, which resulted in aggregation. In addition,
residual PEG, which leaks through the dialysis membrane,
might interfere with further applications of the VLPs [19].
Our data clearly demonstrate that the puriﬁcation process
affectstheintegrityofthenativequaternarystructureofNoV
VLPs and, subsequently, the receptor-binding functionality
of the VLPs. Although the majority of the VLPs puriﬁed by
the CsCl method seemed intact in the EM image, the differ-
ence fromsucrose-density-gradient-puriﬁed VLPs in HBGA
binding is striking. This result is supported by the recent
ﬁndingthatCsClhasanegativeimpactonthefunctionalityof
VLPs [5]. We also demonstrated that even heat-disrupted
VLPs have binding capability, but intact homogenous VLPs
have a signiﬁcantly greater binding intensity. Standardiza-
tion of the puriﬁcation method for NoV VLPs used in diag-
nostic serological assays and blocking assays [8] would
greatly strengthen the results obtained.
To the best of our knowledge, this is the ﬁrst time that
VLPs puriﬁed by conventional puriﬁcation and concen-
tration methods were compared in terms of yield, purity,
morphological integrity, antigenicity and functionality. The
results show that NoV GII-4 VLPs puriﬁed twice by
sucrose density gradient centrifugation followed by ultra-
ﬁltration maintain their icosahedral capsid structure and
their capacity to bind HBGAs.
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